Literature DB >> 12028026

p53 expression in K562 cells is associated with caspase-mediated cleavage of c-ABL and BCR-ABL protein kinases.

Alessandra M A Di Bacco1, Thomas G Cotter.   

Abstract

The chimaeric BCR-ABL oncoprotein is the molecular hallmark of chronic myeloid leukaemia (CML). Expression of Bcr-Abl has been associated with arrested differentiation as well as resistance to apoptosis. The downstream pathway involved in apoptosis resistance has been extensively studied, whereas the role of Bcr-Abl in cell differentiation is largely unclear. A recent report has shown that Bcr-Abl expression alone is sufficient to increase the number of multipotent and myeloid lineage-committed progenitors in a dose-dependent manner while suppressing the development of committed erythroid progenitors. In accordance with this model, downregulation of c-Abl and Bcr-Abl has been observed during differentiation in different systems, although the mechanism is still largely unknown. To investigate the relationship between erythroid differentiation and c-Abl and Bcr-Abl levels, we induced differentiation in K562 cells using a temperature-inducible p53 mutant (p53Val1335). It was found that p53-induced erythroid differentiation in K562 cells required caspase activity. During this process, caspase-dependent cleavage of c-Abl and Bcr-Abl tyrosine kinases was observed, suggesting a new mechanism for the downregulation of the kinases during erythroid differentiation.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12028026     DOI: 10.1046/j.1365-2141.2002.03468.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  10 in total

1.  Regulation of Endoribonuclease Activity of Alpha-Type Proteasome Subunits in Proerythroleukemia K562 Upon Hemin-Induced Differentiation.

Authors:  Alexey G Mittenberg; Tatyana N Moiseeva; Valeria O Kuzyk; Nickolai A Barlev
Journal:  Protein J       Date:  2016-02       Impact factor: 2.371

2.  Gambogic acid induces apoptosis in imatinib-resistant chronic myeloid leukemia cells via inducing proteasome inhibition and caspase-dependent Bcr-Abl downregulation.

Authors:  Xianping Shi; Xin Chen; Xiaofen Li; Xiaoying Lan; Chong Zhao; Shouting Liu; Hongbiao Huang; Ningning Liu; Siyan Liao; Wenbin Song; Ping Zhou; Shunqing Wang; Li Xu; Xuejun Wang; Q Ping Dou; Jinbao Liu
Journal:  Clin Cancer Res       Date:  2013-12-12       Impact factor: 12.531

3.  A dominant-negative effect drives selection of TP53 missense mutations in myeloid malignancies.

Authors:  Steffen Boettcher; Peter G Miller; Rohan Sharma; Marie McConkey; Matthew Leventhal; Andrei V Krivtsov; Andrew O Giacomelli; Waihay Wong; Jesi Kim; Sherry Chao; Kari J Kurppa; Xiaoping Yang; Kirsten Milenkowic; Federica Piccioni; David E Root; Frank G Rücker; Yael Flamand; Donna Neuberg; R Coleman Lindsley; Pasi A Jänne; William C Hahn; Tyler Jacks; Hartmut Döhner; Scott A Armstrong; Benjamin L Ebert
Journal:  Science       Date:  2019-08-09       Impact factor: 47.728

4.  Disruption of Survivin in K562 cells elevates telomerase activity and protects cells against apoptosis induced by the Bcr-abl kinase inhibitor STI571.

Authors:  Zhanxiang Wang; Louis M Pelus
Journal:  Cancer Ther       Date:  2008

5.  Effective killing of Gleevec-resistant CML cells with T315I mutation by a natural compound PEITC through redox-mediated mechanism.

Authors:  H Zhang; D Trachootham; W Lu; J Carew; F J Giles; M J Keating; R B Arlinghaus; P Huang
Journal:  Leukemia       Date:  2008-04-03       Impact factor: 11.528

6.  Effector caspases and leukemia.

Authors:  Ying Lu; Guo-Qiang Chen
Journal:  Int J Cell Biol       Date:  2011-04-14

7.  Different BCR/Abl protein suppression patterns as a converging trait of chronic myeloid leukemia cell adaptation to energy restriction.

Authors:  Silvia Bono; Matteo Lulli; Vito Giuseppe D'Agostino; Federico Di Gesualdo; Rosa Loffredo; Maria Grazia Cipolleschi; Alessandro Provenzani; Elisabetta Rovida; Persio Dello Sbarba
Journal:  Oncotarget       Date:  2016-12-20

8.  Synergy between proteasome inhibitors and imatinib mesylate in chronic myeloid leukemia.

Authors:  Zheng Hu; Xiao-Fen Pan; Fu-Qun Wu; Li-Yuan Ma; Da-Peng Liu; Ying Liu; Ting-Ting Feng; Fan-Yi Meng; Xiao-Li Liu; Qian-Li Jiang; Xiao-Qin Chen; Jing-Lei Liu; Ping Liu; Zhu Chen; Sai-Juan Chen; Guang-Biao Zhou
Journal:  PLoS One       Date:  2009-07-16       Impact factor: 3.240

9.  Anti-rheumatic agent auranofin induced apoptosis in chronic myeloid leukemia cells resistant to imatinib through both Bcr/Abl-dependent and -independent mechanisms.

Authors:  Xin Chen; Xianping Shi; Chong Zhao; Xiaofen Li; Xiaoying Lan; Shouting Liu; Hongbiao Huang; Ningning Liu; Siyan Liao; Dan Zang; Wenbin Song; Quentin Liu; Bing Z Carter; Q Ping Dou; Xuejun Wang; Jinbao Liu
Journal:  Oncotarget       Date:  2014-10-15

Review 10.  Many cuts to ruin: a comprehensive update of caspase substrates.

Authors:  U Fischer; R U Jänicke; K Schulze-Osthoff
Journal:  Cell Death Differ       Date:  2003-01       Impact factor: 15.828

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.